John Canepa
2021
In 2021, John Canepa earned a total compensation of $449.1K as Chief Financial Officer at Candel Therapeutics, a 66% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $74,000 |
|---|---|
| Salary | $370,000 |
| Other | $5,123 |
| Total | $449,123 |
Canepa received $370K in salary, accounting for 82% of the total pay in 2021.
Canepa also received $74K in non-equity incentive plan and $5.1K in other compensation.
Rankings
In 2021, John Canepa's compensation ranked 10,953rd out of 12,415 executives tracked by ExecPay. In other words, Canepa earned more than 11.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,953 out of 12,415 | 12th |
Division Manufacturing | 4,829 out of 5,505 | 12th |
Major group Chemicals And Allied Products | 2,159 out of 2,375 | 9th |
Industry group Drugs | 1,920 out of 2,096 | 8th |
Industry Biological Products, Except Diagnostic Substances | 421 out of 449 | 6th |
Source: SEC filing on September 2, 2022.
Canepa's colleagues
We found three more compensation records of executives who worked with John Canepa at Candel Therapeutics in 2021.